June 6, 2018
…can block inflammation in mice with a naturally occurring antibody that binds oxidized phospholipids (OxPL), molecules on cell surfaces that get modified by inflammation. Even while on a high-fat diet, the antibody protected the mice from arterial plaque formation, hardening of the arteries and liver disease, and prolonged their lives.
September 16, 2014
Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults.
June 21, 2022
A new combination therapy to combat cancer could one day consist of a plant virus and an antibody that activates the immune system’s “natural killer” cells, shows a study by UC San Diego researchers. In mouse models of colon cancer, the therapy eliminated all tumors and prevented their recurrence.
May 14, 2020
…a personalized repertoire of antibodies to protect against invading pathogens. They may also shed light on why some people have a more effective immune response to an infection. “This study will be particularly helpful as dozens of groups begin testing potential COVID-19 vaccines, and see that the vaccine works on…
September 5, 2016
Biochemists at the University of California San Diego have uncovered patterns in the outer protein coat of group A Streptococcus that could finally lead to a vaccine against this highly infectious bacteria—responsible for more than 500,000 deaths a year, including toxic shock syndrome and necrotizing fasciitis or “flesh-eating disease.”
January 28, 2021
…approach, which would use antibody-rich infusions, can either reduce disease symptoms or prevent infections after exposure to SARS-CoV-2 Parallel to COVID-19 vaccination efforts, physicians and researchers at UC San Diego Health, with collaborators across the country, are conducting a pair of clinical trials to assess whether convalescent plasma (CP) therapy…
May 6, 2022
UC San Diego researchers describe the underlying signaling pathway that results in pulmonary arterial hypertension and a novel monoclonal antibody therapy that blocks the abnormal blood vessel formation characterizing the disease.
October 27, 2016
…study also shows that inhibiting CD98 with the therapeutic antibody IGN523 blocks AML growth in patient-derived cells and mouse models.
October 4, 2016
Many types of cancer become drug resistant, making them difficult to treat. Researchers with University of California San Diego School of Medicine and Moores Cancer Center have identified a strategy to selectively sensitize certain cancer cells to radiation therapy that may improve tumor control and reduce treatment-related side effects.
August 13, 2014
Our immune system copes with a multitude of threats using a mix-and-match system to create millions of different antibodies.
